Dr. Ge Li Receives Executive of the Year Award from SCRIP

SHANGHAI, Dec. 7, 2015 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that Dr. Ge Li, WuXi's Chairman and CEO, was named Executive of the Year at the 11th annual SCRIP Awards on December 2 in London.  Established by SCRIP Intelligence, a leading industry news and strategic analysis firm covering the global pharmaceutical and biotech industry, the annual SCRIP Awards recognize the industry's highest achievements by both companies and individuals across the value chain.

Dr. Li was recognized for his vision in building an open-access R&D capability and technology platform to help advance innovative medicines more efficiently and cost effectively.  Under his exemplary leadership, WuXi platform is enabling the efforts of more than 2,000 collaborative partners worldwide and contributing to breakthrough therapies that are profoundly improving patients' lives.  

"I am deeply honored and inspired by this award," said Dr. Li.  "I would like to thank our many customers and partners for their tremendous support for our efforts.  It has been our great privilege to help bring some of the most innovative healthcare products closer to patients."

About WuXi PharmaTech

WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process.  WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit http://www.wuxiapptec.com.

For more information, please contact:

Ronald Aldridge (for investors)
LaVoieHealthScience
+1 617-374-8800 x109 
+1 617-792-2459 
[email protected]  

Aaron Shi (for media)
Director, Corporate Communications
WuXi PharmaTech 
+86-21-5046-4362
[email protected]

SOURCE WuXi PharmaTech (Cayman) Inc.

Related Links

http://www.wuxiapptec.com